Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.33 USD | -0.29% | +8.90% | +23.09% |
Financials (USD)
Sales 2024 * | 167M | Sales 2025 * | 301M | Capitalization | 1.57B |
---|---|---|---|---|---|
Net income 2024 * | -31M | Net income 2025 * | 91M | EV / Sales 2024 * | 9.79 x |
Net Debt 2024 * | 66.33M | Net cash position 2025 * | 5.71M | EV / Sales 2025 * | 5.2 x |
P/E ratio 2024 * |
-250
x | P/E ratio 2025 * |
7.08
x | Employees | 154 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.1% |
Latest transcript on Avadel Pharmaceuticals plc
1 day | -0.29% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Thomas McHugh
DFI | Director of Finance/CFO | 59 | 19-12-01 |
Scott Macke
COO | Chief Operating Officer | - | 14-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Ende
BRD | Director/Board Member | 55 | 18-11-30 |
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Mark McCamish
BRD | Director/Board Member | 72 | 19-12-04 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 17.33 | -0.29% | 1,332,515 |
24-04-18 | 17.38 | -3.39% | 1,108,188 |
24-04-17 | 17.99 | -0.55% | 1,610,132 |
24-04-16 | 18.09 | +6.41% | 2,316,062 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.09% | 1.57B | |
+24.60% | 672B | |
+24.08% | 550B | |
-5.63% | 351B | |
+15.37% | 317B | |
+7.38% | 292B | |
+3.26% | 211B | |
+0.78% | 203B | |
-9.69% | 144B | |
-6.63% | 141B |
- Stock Market
- Equities
- AVDL Stock